Web2. feb 2024 · The primary research question is to evaluate the apixaban utilization according to the approved SPAF indication and recommendations by EMA. In addition a comparison with a cohort of NVAF patients treated with VKA, dabigatran and rivaroxaban for the SPAF indication will also be performed. Objective 1: To characterize patients using apixaban ... Web28. okt 2024 · Apixaban B0661076 NON-INTERVENTIONAL STUDY PROTOCOL Final, 15-Feb-2016 CT24-GSOP-RF03 NI Study Protocol Template; Version 3.0, Effective Date 10-Oct-2014 Pfizer Confidential Page 1 of 28 NON-INTERVENTIONAL (NI) STUDY PROTOCOL Study information Title Apixaban drug utilization study in Stroke prevention in atrial fibrillation …
doi: 10.1111/joim.12138 Advantages and limitations of the new ...
Web12. okt 2024 · The indication for anticoagulation was SPAF in the majority of the patients (n = 63; 75.0%). There were 45 MBEs for patients on rivaroxaban and 39 MBEs for patients … Web1. apr 2024 · All 4 NOACs have been tested against dose-adjusted warfarin in well-designed, pivotal, phase III, randomized, controlled trials (RCTs) and were approved by regulatory authorities for an SPAF ... copper city bar and grill ansonia ct
Prescribing Information (SPAF and DVT/PE - Boehringer Ingelheim
Webapproved SPAF indication and recommendations by EMA. In addition a comparison with a cohort of NVAF patients treated with VKA, dabigatran and rivaroxaban for the SPAF indication will also be performed. Objective 1: To characterize patients using apixaban according to demographics, comorbidity, risk of thromboembolic events (CHADS Webinhibitor for the SPAF indication, achieving statistically significant reduction in stroke and bleeding relative to warfarin at a single dose level (Granger et al. 2011). ... Results indicate that modulation of fIXa inhibits throm-bosis and may represent a novel, promising antithrom-botic strategy. Materials and Methods WebApixaban drug utilization study for Stroke prevention in atrial fibrillation (SPAF). Rationale and background Apixaban is a direct oral anticoagulant, which inhibits the factor Xa. Its … copper city brewery rome new york